Laws and Labels: A Regulatory View of Biosimilars

Friday, October 30, 2015
Presented by: 
Erika Lietzan

Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.

You may also like:

Blog Post

“Staying informed is more important than ever given the changing market dynamics of healthcare.” I have been fortunate to attend the National A...

View Blog Post
Blog Post

A paper in the Perspectives section of the New England Journal of Medicine (Feb 22 issue, 2018) discussed the problem of benzodiazepine abuse, examining both the ...

View Blog Post
Blog Post

At the time of this writing, a record 52.2 inches of rain had fallen on the Big Island o...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up